Home nursing, home physiotherapy, home dialysis and infusion, remote monitoring and post-acute care in the UAE, Saudi Arabia and India: market size, licensing, insurer coverage, providers and the economics.
Home healthcare — skilled nursing, rehabilitation, home dialysis and infusion, respiratory support, remote monitoring and post-acute care delivered in the patient’s home — is one of the fastest-growing service segments in the GCC and India. Published estimates for 2025 range from USD 8.8 bn to USD 8.8 bn; our central estimate is USD 8.8 bn, growing at about 9% to USD 16.1 bn by 2032.
Three forces drive it: payers want long-stay and post-acute patients out of expensive hospital beds (UAE insurers and DoH/DHA have home-care tariffs; Saudi clusters contract home care); ageing and chronic disease increase the need; and hospital groups see home care as both a capacity release and a new service line. In India, organised home-care providers have emerged in metros with hospital partnerships and insurer pilots.
The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 8.8 bn–USD 8.8 bn; differences are mostly scope.
| Publisher (date) | Base value | Forecast | CAGR |
|---|---|---|---|
| IMARC Group (2025) — GCC home healthcare (products + services); 2026 est. USD 9.6 | USD 8.8 bn (2025) | USD 19.0 bn (2034) | 8.98% (2026-2034) |
| Mordor Intelligence (2025) — UAE home healthcare (products, services, software); 2026 est | USD 1.18 bn (2025) | USD 2.19 bn (2031) | 10.84% (2026-2031) |
| Nexdigm (UAE Home Care Market Outlook to 2035) (2025) — UAE home care market; headline figure, base year not stated | USD 2.2 bn () | — (2035) | 10.8% |
| IMARC Group (2025) — Saudi Arabia home healthcare (products 57.3% / services 42.7 | USD 4.21 bn (2025) | USD 7.58 bn (2034) | 6.75% (2026-2034) |
| Mordor Intelligence (2025) — India home healthcare (equipment, software, services); USD 9 | USD 11.90 bn (2025) | USD 27.38 bn (2030) | 18.13% (2025-2030) |
| Coherent Market Insights (via GlobeNewswire) (2025-11) — Global home healthcare; products 50.6% share; North America | USD 435.23 bn (2025) | USD 770.92 bn (2032) | 8.5% (2025-2032) |
| Research and Markets (via BusinessWire) (2025-10) — Global home healthcare forecast to 2030 (headline only) | None () | USD 473.8 bn (2030) | — |
| Consulting Wallah central estimate | USD 8.8 bn (2025) | USD 16.1 bn (2032) | ~9% |
Source: Publisher pages as listed under Sources; CW estimate as described in Method.
Included: licensed home nursing and allied health, home medical equipment and supplies, home dialysis and infusion services, remote monitoring tied to clinical services. Excluded: unlicensed domestic care; consumer devices without services. Licensing: DoH and DHA home-care licences (UAE); MoH (Saudi); state clinical establishment acts (India).
Shares as reported by the named sources; ranking is more reliable than the exact percentage.
| Segment | Share | Note | |
|---|---|---|---|
| Therapeutic products | 46.28% | largest | |
| Mobility care products | 11.21% | fastest |
Source: Mordor Intelligence https://www.mordorintelligence.com/industry-reports/market-entry-home-healthcare-industry-in-uae
| Segment | Share | Note | |
|---|---|---|---|
| Rehabilitation therapy | 37.74% | largest | |
| Respiratory therapy | 11.37% | fastest |
Source: Mordor Intelligence
| Segment | Share | Note | |
|---|---|---|---|
| Chronic respiratory diseases | 40.98% | largest | |
| Cancer & palliative care | 11.62% | fastest |
Source: Mordor Intelligence
| Segment | Share | Note | |
|---|---|---|---|
| Products | 57.3% | ||
| Services | 42.7% | fastest, ~8.2% CAGR |
Source: IMARC https://www.imarcgroup.com/saudi-arabia-home-healthcare-market
| Segment | Share | Note | |
|---|---|---|---|
| Cardiovascular & hypertension | 18.6% | largest | |
| Diabetes | 15.9% | ||
| Cancer | 12.7% | 9-10% CAGR | |
| Wound care | 10.6% | ||
| Movement disorders | 9.4% |
Source: IMARC
| Segment | Share | Note | |
|---|---|---|---|
| Northern & Central | 31.4% | ||
| Western | 27.6% | fastest ~7.2% CAGR | |
| Eastern | 22.8% | ||
| Southern | 18.2% |
Source: IMARC
| Segment | Share | Note | |
|---|---|---|---|
| Products | 50.6% | ||
| North America | 40% | ||
| Cardiovascular & hypertension indication | 25% |
Source: Coherent Market Insights
| Country / region | Figure | Year | Source |
|---|---|---|---|
| GCC home healthcare market | USD 8.8 bn (2025) to USD 19.0 bn (2034) | 2025 | IMARC |
| UAE home healthcare market | USD 1.18 bn (2025) to USD 2.19 bn (2031) | 2025 | Mordor Intelligence |
| Dubai licensed home care facilities | 249 (H1 2026) vs 203 (H1 2025), +22.7% | 2026 | DHA via Khaleej Times |
| Saudi Arabia home healthcare market | USD 4.21 bn (2025) to USD 7.58 bn (2034) | 2025 | IMARC |
| Saudi MoH home healthcare programme | 58,000+ active cases/yr; 71,000+ beneficiaries since launch; 244 departments; 2,700+ staff | 2024 | Arab News / SPA |
| India home healthcare market | USD 11.90 bn (2025) to USD 27.38 bn (2030); USD 9.74 bn (2024) | 2025 | Mordor Intelligence |
| Global home healthcare market | USD 435.23 bn (2025) to USD 770.92 bn (2032) | 2025 | Coherent Market Insights |
Source: Sources as named; see Sources and method.
UAE providers (Burjeel, Mediclinic, NMC, Aster, Amana, HealthPlus, Emirates Home Nursing) are licensed by DoH/DHA; insurers cover defined home-care packages; Saudi clusters outsource home care under the model-of-care reform; long-stay discharge programmes are the volume driver.
Portea, Nightingales (Medwell), HealthCare atHome, Apollo HomeCare and hospital-linked providers serve metros; insurer coverage is nascent; demand is strong for post-surgical, elderly and critical-care-at-home services.
| Date | Development | Source |
|---|---|---|
| 2025-01 | Saudi MoH reports 58,000+ active home healthcare cases, 244 home healthcare departments and 2,700+ specialised staff under the Health Sector Transformation Program. | Arab News |
| 2025-01 | UAE compulsory national health insurance takes effect nationwide on 1 January 2025, extending home-care reimbursement. | Mordor Intelligence |
| 2025-06 | Aveanna Healthcare completes acquisition of Thrive Skilled Pediatric Care, expanding US paediatric home care. | Coherent Market Insights |
| 2025-11 | Coherent Market Insights projects global home healthcare market to USD 770.92 bn by 2032 at 8.5% CAGR. | GlobeNewswire |
| 2026-10 | DHA reports licensed home healthcare facilities in Dubai rose 22.7% to 249 in H1 2026, the fastest-growing facility category. | Khaleej Times |
| 2026-10 | Saudi CCHI confirms mandatory health insurance covers home healthcare services (catheterisation, post-op IV medication, wound care) with MoH e-application. | Gulf News |
Source: Company and press announcements as named.
Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.
Published estimates normalised to 2025 range from USD 8.8 bn to USD 8.8 bn. Consulting Wallah’s central estimate is USD 8.8 bn in 2025, rising to about USD 16.1 bn by 2032.
Published CAGRs range from 8.98% to 8.98%; our central case is about 9% a year to 2032.
NMC Healthcare (ProVita / home care), Sublime Nursing, DB Health Group, Emirates Home Nursing, THB Home Health Care LLC, Call My Doctor, First Response Healthcare, ES Healthcare Centre among others.
The summary on this page is free to read and share with attribution. The full report is free for hospital leaders and registered Consulting Wallah Network members, and priced on request for others.
The full report (PDF, 40 pages) adds the GCC and India deep-dives, hospital-level benchmarks from the Consulting Wallah Network and the full source tables. Free for hospital leaders and registered network members; otherwise priced on request.
How to read these figures. Published market-size estimates for this market vary widely because publishers define scope differently (software only vs software + services + logistics). Where we show a Consulting Wallah estimate we state the range of published figures it is triangulated from and our scope. Figures marked as reported are quoted from the named source. Nothing here is investment advice.